Effects of D-003 on hepatic drug-metabolizing enzyme activities in rats

Journal of Medicinal Food

Volumn 7, Issue 4, 2004, Pages 482-486

  Gámez, Rafael ^a   Rodeiro, Idania ^a   González, Jorge ^a   García, Haydee ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Anti platelet effects; Cholesterol lowering effects; D 003; Microsomal cytochrome P 450 system

Indexed keywords

AMINOPYRINE N DEMETHYLASE; CYTOCHROME B5; CYTOCHROME P450; D 003; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLIZING ENZYME; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE TRANSFERASE; PENTOXYRESORUFIN DEALKYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; THIOL DERIVATIVE; THIOL GROUP;

ACACIA; ANIMAL EXPERIMENT; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; FEEDING; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ACACIA; ANIMALIA;

EID: 11844306539     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2004.7.482     Document Type: Article

References (40)

1. Nebert DW, Nelson DR, Coon MJ, Estabrook EW, Feyereisen R: The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991;10:1-14.
2. Ingelman-Sundberg M, Oscarson I, Persson C, Masimirembwa M, Bertilsson C, Dahl M: Genetic polymorphism of human drug metabolism enzymes. Recent aspects on polymorphic forms of cytochromes P-450. FEBS Lett 1998;2:93-108.
3. Guengerich CP: Analysis and characterisation of enzymes and nucleic acids. In Principles and Methods of Toxicology, 4th ed. (Wallace A, ed.), Raven Press, New York, 2001, pp. 1625-1688.
4. Stevens K, Gallo M: Practical considerations in the conduct of chronic toxicity studies. In Principles and Methods of Toxicology, 2nd ed. (Wallace A, ed.), Raven Press, New York, 1989, pp. 237-250.
5. González L, Marrero D, Laguna A, Más R, Arruzazabala ML, Carbajal D, inventors; Laboratorios Dalmer, SA, Havana, Cuba, assignee: A mixture of primary fatty acids obtained from sugar cane wax. US patent 6,486.205. November 20, 2002.
6. Gámez R, Mendoza S, Más R, Mesa R, Castaño G, Marrero D: Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr The r Res 2000;61:8-16.
7. Mendoza S, Gámez R, Noa M, Más R, Castaño G, Mesa R, Mesa M, de Armas M: The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001;62:209-220.
8. Gámez R, Mendoza S, Mas R, Noa M, Arruzazabala ML, Carbajal D, Castaño G, Goicochea E, Mesa M, Mendoza N: Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolaemic rabbits. Drugs Dev Res 2003;4:219-229.
9. Mendoza S, Gámez R, Mas R, Goicochea E: Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int J Tissue React 2003;25(3): 81-89.
10. Castaño G, Más R, Fernández L, Illnait J, Gámez R, López E, Gutierrez J, Fernández J, Alvarez E: Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound on healthy volunteers: a Phase I clinical study. Drugs Dev Res 2002;3:337-348.
11. Castaño G, Mas R, Fernández L, Illnait J, Fernández J, Mendoza S, Gámez R, Mesa M, Lopez E, Alvarez E: Effects of D-003 (5-40 mg/day) on lipid profile of patients with Type II hypercholesterolemia: a Phase II clinical study. Clin Drug Invest 2003;23: 789-802.
12. Castaño G, Menéndez R, Más R, Ledón N, Fernández JC, Pérez JL. Gonzalez RM, Lescay M: Effects of D-003: a new hypocholesterolaemic and antiplatelet compound on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003;23:193-203.
13. Arruzazabala M, Carbajal D, Más R, Molina V, Castaño G, Gámez R: Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: a randomized, double-blind clinical study. Clin Drug Invest 2002;23:107-118.
14. Molina V, Arruzazabala ML, Carbajal D, Más R, Valdés, S: Antiplatelet and antithrombotic effect of D-003. Pharmacol Res 2000;42:137-143.
15. Molina V, Arruzazabala L, Carbajal D, Más R: D-003 a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites. Prostaglandins Leukot Essent Fatty Acids 2002;67:19-24.
16. Molina V, Arruzazabala ML, Carbajal D, Más R: Synergistic effect of D-003 and aspirin on experimental thrombosis models. Prostaglandins Leukot Essent Fatty Acids 2003;68:305-310.
17. Arruzazabala ML, Molina V, Carbajal D, Más R: D-003 and warfarin interaction on the bleeding time and venous thrombosis experimentally induced in rats. J Med Food 2004;7:260-263.
18. Gámez R, Más R, Noa M: Acute and oral subchronic toxicity of D-003 in rats. Toxicol Lett 2000;118:1-2, 31-41.
19. Gámez R, Más R, Noa M, Menéndez R, Garcia H, González JE, Perez Y, Goicochea E: Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drug Res Dev 2002;3:375-386.
20. Gámez R, Más R, Noa M, Menéndez R, García H, González J, Pérez Y, Goicochea E: Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle dogs. Drugs Exp Clin Res 2004;30(2):75-88.
21. Gámez R, Rodeiro I, Fernández I, Acosta P: Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: mixture of very long chain aliphatic acids. Teratog Carcinog Mutagen 2002;22:175-181.
22. Gámez R, González JE, Rodeiro I, Fernández I, Alemán C, Rodríguez M, Acosta P, García H: In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic acids. J Med Food 2001;4:85-91.
23. Rodriguez MD, Gámez R, Gonzalez JE, Garcia H, Acosta CP, Goicochea E: Lack of developmental toxicity of D-003: a mixture of long chain fatty acids in rats. Food Chem Toxicol 2003;41:89-93.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-269.
25. Omura T, Sato R: The carbon monoxide binding pigment of liver microsomes. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-2373.
26. Nash T: The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 1953;193:265-275.
27. Weibel, ER, Staubli W, Gnagi HR. Hess FA: Correlated morphometric and biochemical studies on liver cell. J Cell Blol 1969;42:68-70.
28. Donato MT, Gómez-Lechón MJ, Castell J: Actividad etoxiresorufina O-deetilasa en placa de cultivo. Anal Biochem 1993;213:29-33.
29. Williams JC, Kamin H: The preparation and properties of microsomal TPNH-cytochrome c reductase from pig liver. J Biol Chem 1962;237:587-595.
30. Sedlak J, Lindsay R: Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-195.
31. Habig WH, Jakoby WB: Glutathione S-transferase. The first step in mercapturic acid formation. J Biol Chem 1974;249:2130-2132.
32. Claiborne A. Catalase activity. In CRC Handbook of Methods for Oxygen Radical Research (Greenwald RA, ed.), CRC Press, Boca Raton, FL, 1985, pp. 283-284.
33. González F, Gelboin HV: Role of human cytochromes P-450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1995;26:165-183.
34. Ashby J, Brady A, Elliot B, Ismael J, Odum J, Tugwood J, Kettle S, Purchase I: Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 1994;13(2):34-38.
35. De Master EG, Redfern B: High performance liquid chromatography of hepatic thiols with electrochemical detection. Methods Enzymol 1987;143:110-116.
36. Perez Y, Menendez R, Mas R, Gonzalez R, Ledon N, Jimenez S: Efectos de la administración oral de D-003 sobre la peroxidacion lipidica "in vivo" e "in vitro" en higados de ratas. Rev Cub Farm 2002;36(Supl Esp):75-76.
37. Ledón N, Menéndez R, Más R, Amor AM, Pérez Y, González RM, Jiménez S: Effects of oral administration of D-003 a mixture of very long-chain saturated fatty acid on rat lipoprotein lipid peroxidation. Rev Cub Farm 2002;36(Supl Esp):91-94.
38. Menéndez R, Más R, Amor AM, Ledon N, Perez Y, Gonzalez RM, Rodeiro I, Zayas M, Jimenez S: Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002;80:13-21.
39. 4C-induced liver acute injury in rats. Drugs Exp Clin Res 2002;28:177-183.
40. McKindley MC, Dufresne R: Current knowledge of the cytochrome P-450 isoenzyme system: can we predict clinically important drug interactions. Med Health 1998;81:38.